PLX

#3743
Protalix BioTherapeutics, Inc. Common Stock
2.2 2 USD
+9.90%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
2.12
2.23
Year Range
1.88
3.19
Daily Change
+9.90%
Monthly Change
+15.63%
6 month change
-23.97%
Year Change
-23.97%
Previous Close
2.0 2
Open
2.1 2
Low
2.1 2
High
2.2 3
Volume
842
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 178.87 M
  • Employee 226
  • Founded 1993
  • CEO Dror Bashan
  • Website www.protalix.com
  • Headquarter Delaware, United States
  • FIGI BBG000JW08N5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-22.5
Price to sales ratio
2.68

Protalix BioTherapeutics, Inc. Common Stock

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

News